In 558 infants with severe HIV-associated pneumonia in Africa, adding 15 days of valganciclovir to standard care did not significantly reduce day-15 deaths (23% vs 27%; rate ratio 0·81, p=0·15) or 12-month deaths (43% vs 48%); a time-varying model gave day-15 HR 0·60.
RCTn = 558
Moraleda et al. Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial